1-2 of 2
William Donnellan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

Open Access
Clinical Trials & Observations
Jorge E. Cortes, Jay Yang, Gail J. Roboz, Shira N. Dinner, Eunice S. Wang, Andrew H. Wei, Hua Tian, Francois di Trapani, Maria R. Baer, William Donnellan, Justin M. Watts
Journal: Blood Advances
Blood Adv (2025) 9 (20): 5293–5305.
https://doi.org/10.1182/bloodadvances.2025016718
Published: 2025
Includes: Supplemental data
Journal Articles

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

Free
Clinical Trials & Observations
Aaron T. Gerds, Bart L. Scott, Peter Greenberg, Tara L. Lin, Daniel A. Pollyea, Amit Verma, Monique Dail, Yuning Feng, Cherie Green, Connie Ma, Bruno C. Medeiros, Mark Yan, Kasra Yousefi, William Donnellan
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1152–1161.
https://doi.org/10.1182/bloodadvances.2021005240
Published: 2022
Includes: Supplemental data